Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.
Obesity is highly associated with elevated serum triglycerides, hepatic steatosis and type 2 diabetes (T2D). The I148M (rs738409) genetic variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is known to modulate hepatic triglyceride accumulation, leading to steatosis. No associati...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3377675?pdf=render |
| _version_ | 1818510530883616768 |
|---|---|
| author | Colin N A Palmer Cristina Maglio Carlo Pirazzi Maria Antonella Burza Martin Adiels Lindsay Burch Louise A Donnelly Helen Colhoun Alexander S Doney John F Dillon Ewan R Pearson Mark McCarthy Andrew T Hattersley Tim Frayling Andrew D Morris Markku Peltonen Per-Arne Svensson Peter Jacobson Jan Borén Lars Sjöström Lena M S Carlsson Stefano Romeo |
| author_facet | Colin N A Palmer Cristina Maglio Carlo Pirazzi Maria Antonella Burza Martin Adiels Lindsay Burch Louise A Donnelly Helen Colhoun Alexander S Doney John F Dillon Ewan R Pearson Mark McCarthy Andrew T Hattersley Tim Frayling Andrew D Morris Markku Peltonen Per-Arne Svensson Peter Jacobson Jan Borén Lars Sjöström Lena M S Carlsson Stefano Romeo |
| author_sort | Colin N A Palmer |
| collection | DOAJ |
| description | Obesity is highly associated with elevated serum triglycerides, hepatic steatosis and type 2 diabetes (T2D). The I148M (rs738409) genetic variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is known to modulate hepatic triglyceride accumulation, leading to steatosis. No association between PNPLA3 I148M genotype and T2D in Europeans has been reported. Aim of this study is to examine the relationship between PNPLA3 I148M genotypes and serum triglycerides, insulin resistance and T2D susceptibility by testing a gene-environment interaction model with severe obesity.PNPLA3 I148M was genotyped in a large obese cohort, the SOS study (n = 3,473) and in the Go-DARTS (n = 15,448), a T2D case-control study. Metabolic parameters were examined across the PNPLA3 I148M genotypes in participants of the SOS study at baseline and at 2- and 10-year follow up after bariatric surgery or conventional therapy. The associations with metabolic parameters were validated in the Go-DARTS study. Serum triglycerides were found to be lower in the PNPLA3 148M carriers from the SOS study at baseline and from the Go-DARTS T2D cohort. An increased risk for T2D conferred by the 148M allele was found in the SOS study (O.R. 1.09, 95% C.I. 1.01-1.39, P = 0.040) and in severely obese individuals in the Go-DARTS study (O.R. 1.37, 95% C.I. 1.13-1.66, P = 0.001). The 148M allele was no longer associated with insulin resistance or T2D after bariatric surgery in the SOS study and no association with the 148M allele was observed in the less obese (BMI<35) individuals in the Go-DARTS study (P for interaction = 0.002). This provides evidence for the obesity interaction with I48M allele and T2D risk in a large-scale cross-sectional and a prospective interventional study.Severely obese individuals carrying the PNPLA3 148M allele have lower serum triglyceride levels, are more insulin resistant and more susceptible to T2D. This study supports the hypothesis that obesity-driven hepatic lipid accumulation may contribute to T2D susceptibility. |
| first_indexed | 2024-12-10T23:21:14Z |
| format | Article |
| id | doaj.art-bc3e6f50135a4898a4023596edf31302 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T23:21:14Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-bc3e6f50135a4898a4023596edf313022022-12-22T01:29:43ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0176e3936210.1371/journal.pone.0039362Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.Colin N A PalmerCristina MaglioCarlo PirazziMaria Antonella BurzaMartin AdielsLindsay BurchLouise A DonnellyHelen ColhounAlexander S DoneyJohn F DillonEwan R PearsonMark McCarthyAndrew T HattersleyTim FraylingAndrew D MorrisMarkku PeltonenPer-Arne SvenssonPeter JacobsonJan BorénLars SjöströmLena M S CarlssonStefano RomeoObesity is highly associated with elevated serum triglycerides, hepatic steatosis and type 2 diabetes (T2D). The I148M (rs738409) genetic variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is known to modulate hepatic triglyceride accumulation, leading to steatosis. No association between PNPLA3 I148M genotype and T2D in Europeans has been reported. Aim of this study is to examine the relationship between PNPLA3 I148M genotypes and serum triglycerides, insulin resistance and T2D susceptibility by testing a gene-environment interaction model with severe obesity.PNPLA3 I148M was genotyped in a large obese cohort, the SOS study (n = 3,473) and in the Go-DARTS (n = 15,448), a T2D case-control study. Metabolic parameters were examined across the PNPLA3 I148M genotypes in participants of the SOS study at baseline and at 2- and 10-year follow up after bariatric surgery or conventional therapy. The associations with metabolic parameters were validated in the Go-DARTS study. Serum triglycerides were found to be lower in the PNPLA3 148M carriers from the SOS study at baseline and from the Go-DARTS T2D cohort. An increased risk for T2D conferred by the 148M allele was found in the SOS study (O.R. 1.09, 95% C.I. 1.01-1.39, P = 0.040) and in severely obese individuals in the Go-DARTS study (O.R. 1.37, 95% C.I. 1.13-1.66, P = 0.001). The 148M allele was no longer associated with insulin resistance or T2D after bariatric surgery in the SOS study and no association with the 148M allele was observed in the less obese (BMI<35) individuals in the Go-DARTS study (P for interaction = 0.002). This provides evidence for the obesity interaction with I48M allele and T2D risk in a large-scale cross-sectional and a prospective interventional study.Severely obese individuals carrying the PNPLA3 148M allele have lower serum triglyceride levels, are more insulin resistant and more susceptible to T2D. This study supports the hypothesis that obesity-driven hepatic lipid accumulation may contribute to T2D susceptibility.http://europepmc.org/articles/PMC3377675?pdf=render |
| spellingShingle | Colin N A Palmer Cristina Maglio Carlo Pirazzi Maria Antonella Burza Martin Adiels Lindsay Burch Louise A Donnelly Helen Colhoun Alexander S Doney John F Dillon Ewan R Pearson Mark McCarthy Andrew T Hattersley Tim Frayling Andrew D Morris Markku Peltonen Per-Arne Svensson Peter Jacobson Jan Borén Lars Sjöström Lena M S Carlsson Stefano Romeo Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS ONE |
| title | Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. |
| title_full | Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. |
| title_fullStr | Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. |
| title_full_unstemmed | Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. |
| title_short | Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. |
| title_sort | paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the pnpla3 148m variant |
| url | http://europepmc.org/articles/PMC3377675?pdf=render |
| work_keys_str_mv | AT colinnapalmer paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT cristinamaglio paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT carlopirazzi paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT mariaantonellaburza paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT martinadiels paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT lindsayburch paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT louiseadonnelly paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT helencolhoun paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT alexandersdoney paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT johnfdillon paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT ewanrpearson paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT markmccarthy paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT andrewthattersley paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT timfrayling paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT andrewdmorris paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT markkupeltonen paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT perarnesvensson paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT peterjacobson paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT janboren paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT larssjostrom paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT lenamscarlsson paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant AT stefanoromeo paradoxicallowerserumtriglyceridelevelsandhighertype2diabetesmellitussusceptibilityinobeseindividualswiththepnpla3148mvariant |